Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252955 | 0.81 | HCRTR1 (0.43) | — | |
| SCHEMBL979251 | 0.80 | ATR (0.50) | RAB9A | |
| SCHEMBL16826513 | 0.77 | HCRTR1 (0.42) | L3MBTL1 | |
| SCHEMBL14284386 | 0.76 | NPC1 (0.61) | NPC1LMNAMETAP2RAB9AMETAP1 | |
| SCHEMBL27622181 | 0.75 | NPC1 (0.66) | NPC1LMNAMETAP2RAB9AMETAP1 | |
| SCHEMBL18039131 | 0.74 | HCRTR1 (0.44) | L3MBTL1 | |
| SCHEMBL23752387 | 0.73 | METAP1 (0.68) | METAP1 | |
| SCHEMBL21067821 | 0.69 | METAP1 (0.73) | METAP1 | |
| SCHEMBL1897970 | 0.68 | NPC1 (1.00) | NPC1LMNAMETAP2RAB9AMETAP1 | |
| SCHEMBL7016457 | 0.67 | NPC1 (0.70) | NPC1LMNAMETAP2RAB9AMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | NPC1 2818/4885LMNA 1842/4885METAP2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.